Clinical trials: Chemotherapy-Related Nausea and/or Vomiting
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors
RATIONALE: Mindfulness relaxation, a technique to help patients quiet their thoughts and relax their bodies before and during chemotherapy, may reduce or prevent nausea and vomiting.
- Conditions
- Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific, Breast Cancer, Gastrointestinal Cancer
- Trial name
- NCT00086762
- Testing
- MR Therapy, Relaxing Music (RM) Therapy, Standard Symptom Management
- Where
- 9 sites in United States
- Volunteers
- 474 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Cancer
Aloxi for Prevention of Chemotherapy Induced Nausea and Vomiting in Malignant Glioma Patients Receiving Irinotecan With Bevacizumab
1. Primary Objective: To determine the efficacy and tolerability of palonosetron and dexamethasone in preventing acute CINV in brain tumor patients during the first 24 hours of receiving Irinotecan /Bevacizumab regimens. 2.
- Trial name
- NCT00636805
- Testing
- Palonosetron (Aloxi) and Dexamethasone
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Duke University
Complete Response Rate to Chemotherapy-induced Nausea and Vomiting Prophylaxis
Olanzapine for Chemotherapy-induced Nausea and Vomiting Prophylaxis
To investigate that olanzapine can reduced side effect about nausea and vomiting in women with gynecologic cancers receiving carboplatin-based regimen by using olanzapine and placebo
- Trial name
- OLN-EME (NCT04232423)
- Testing
- Olanzapine 10 Mg ORAL TABLET, Olanzapine 5 Mg ORAL TABLET
- Where
- Thailand
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Emesis
Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.
For breast cancer patients receiving chemotherapy regimens, the use of a validated emesis (nausea and vomiting) risk calculator will provide superior anti-emetic (nausea and vomiting) control compared with "standard" anti-emetic…
- Trial name
- ER11-02 (NCT01913990)
- Testing
- Dexamethasone, Ondansetron, Aprepitant, Arm A: Standard Anti-emetic regimen
- Where
- Canada
- Volunteers
- 323 people
- Sponsor
- Ottawa Hospital Research Institute
Chemotherapy-induced Nausea and Vomiting
"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"
Chemotherapy induced nausea and vomiting (CINV) is one of the most distressing toxicities of cancer treatment. It can occur up to 90% in case of highly emetogenic chemotherapy (HEC) use.
- Trial name
- PRaCTiCE (NCT03219710)
- Testing
- Ondansetron, Dexamethasone, Aprepitant
- Where
- India
- Volunteers
- 240 people
- Sponsor
- All India Institute of Medical Sciences
Chemotherapy-induced Nausea and Vomiting
Phase II Proof-of-concept Study of APD421
Evaluation of efficacy of APD421 in preventing nausea and vomiting caused by cisplatin
- Trial name
- NCT01303978
- Testing
- APD421
- Where
- 4 sites in Denmark, United Kingdom
- Volunteers
- 51 people
- Sponsor
- Acacia Pharma Ltd
Chemotherapy-Induced Nausea and Vomiting
A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting
NEPA-15-18 is a clinical study assessing safety of pro-netupitant and palonosetron, two antiemetic drugs, given with oral dexamethasone.
- Trial name
- NCT02517021
- Testing
- Pro-netupitant/Palonosetron, Netupitant/Palonosetron, Dexamethasone
- Where
- 74 sites in United States, Austria and 10 more
- Volunteers
- 405 people
- Sponsor
- Helsinn Healthcare SA
Lymphoma, Non-Hodgkin
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
The incidence and severity of chemotherapy-induced nausea and vomiting (CINV) in patients receiving R-CHOP chemotherapy for in non-Hodgkin's lymphoma is not well documented.
- Trial name
- NCT01843868
- Testing
- Standard anti-emetics in conjunction with R-CHOP
- Sponsor
- Australasian Leukaemia and Lymphoma Group
Nausea, Vomiting
Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)
The management of chemotherapy-induced nausea and vomiting (CINV) has evolved in recent years and became less frequent. CINV include early (occurring within 24 hours of chemotherapy administration) and delayed (occurring within 4…
- Trial name
- NVCI (NCT02767791)
- Testing
- Acupuncture, Auriculotherapy
- Where
- 5 sites in France
- Volunteers
- 116 people
- Sponsor
- Hopital Foch
Chemotherapy-induced Nausea and Vomiting, Lung Cancer
Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer
Chemotherapy induced nausea and vomiting (CINV) is a common adverse effect in treatment of cancer, which influences the quality of life and adherence to treatment of patients and leads to dehydration, malnutrition and even death.
- Trial name
- NCT03571126
- Testing
- Olanzapine
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- Zunyi Medical College
Chemotherapy-induced Nausea and Vomiting (CINV)
Granisetron Transdermal Patch for Prophylaxis of Nausea and Vomiting in Patients Receiving Oral Anticancer Agents
At present, the clinical studies of 5-HT3RA are aimed at nausea and vomiting induced by single-day chemotherapy, but there are many chemotherapy schemes that require multi-day administration in clinical practice.
- Trial name
- NCT04472143
- Testing
- Granisetron Transdermal Delivery System
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fudan University
Chemotherapy-induced Nausea and Vomiting
Prevalence of Delayed Chemotherapy Associated Nausea
This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.
- Trial name
- CINrate (NCT04342780)
- Where
- Switzerland
- Volunteers
- 172 people
- Sponsor
- Antje Koller
Lung Neoplasms
The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting
The purpose of this study is to compare the preventive effect of electroacupuncture and sham acupuncture on acute chemotherapy-induced nausea and vomiting and then investigate its potential mechanism by using functional Magnetic…
- Trial name
- NCT02469493
- Testing
- acupuncture (Huatuo)
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Xidian University
Nausea, Vomiting
A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)
This is an efficacy and safety study to compare aprepitant with ondansetron for the prevention of nausea and vomiting in the first cycle of moderately emetogenic chemotherapy (MEC) in participants with solid tumors.
- Trial name
- KMEC (NCT01636947)
- Testing
- Aprepitant, Ondansetron, Dexamethasone
- Volunteers
- 494 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
Granisetron Transdermal Patch System for Prevention of CINV by CapeOX
This study aims to explore the prevention of delayed chemotherapy induced by CAPOX regimen with granisetron transdermal patch。
- Trial name
- NCT05325190
- Testing
- Granisetron Transdermal Patch System
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chemotherapy Induced Nausea and Vomiting
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children…
- Trial name
- NCT02097823
- Testing
- Olanzapine, Aprepitant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)
This study is designed to assess the safety and efficacy of palonesetron in preventing chemotherapy-induced nausea and vomiting (CINV) when administered to participants who have experienced either vomiting and or at least…
- Trial name
- NCT01054456
- Testing
- palonesetron
- Where
- 9 sites in United States
- Volunteers
- 36 people
- Sponsor
- Eisai Inc.
Oncology, Breast Cancer
Pantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer Chemotherapy
This study explores whether a commonly used medication called Pantoprazole can help prevent delayed nausea and vomiting from chemotherapy for early breast cancer.
- Conditions
- Oncology, Breast Cancer, Chemotherapy-induced Nausea and Vomiting
- Trial name
- PantoCIN (NCT03948477)
- Testing
- Pantoprazole 40mg
- Where
- 10 sites in New Zealand
- Volunteers
- 160 people
- Sponsor
- University of Auckland, New Zealand
Chemotherapy-induced Nausea and Vomiting
Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients
In this study, patients will receive ondansetron 8mg and dexamethasone 10mg intravenously 30 minutes prior to myeloablative preparative chemotherapy until the last day of chemotherapy.
- Trial name
- NCT01370408
- Testing
- Palonosetron, ondansetron, Dexamethasone
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- Northside Hospital, Inc.
Breast Cancer
Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile
The objectives of this study are to determine if pharmacogenetic (PG) analysis of an individual enable optimal selection of antiemetic regimen for patients undergoing the first cycle of AC (Adriamycin + Cyclophosphamide) or FEC…
- Trial name
- NCT07455955
- Testing
- Standard antiemetic regimen or Olanzapine antiemetic regimen
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong